Access cutting-edge post-transplant lymphoproliferative disease treatment through this clinical trial at a research site in La Jolla. Study-provided care at no cost to qualified participants.
Access post-transplant lymphoproliferative disease specialists in La Jolla at no cost
This study follows strict safety protocols and ethical guidelines
All study-related post-transplant lymphoproliferative disease treatment provided free
The purpose of this study is to determine the clinical benefit and characterize the safety profile of tabelecleucel for the treatment of Epstein-Barr virus-associated post-transplant lymphoproliferative disease (EBV+ PTLD) in the setting of (1) solid organ transplant (SOT) after failure of rituximab (SOT-R) and rituximab plus chemotherapy (SOT-R+C) or (2) allogeneic hematopoietic cell transplant (HCT) after failure of rituximab.
Sponsor: Pierre Fabre Medicament
Check if you qualify for this post-transplant lymphoproliferative disease clinical trial in La Jolla, CA
If you're searching for post-transplant lymphoproliferative disease treatment options in La Jolla, CA, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our La Jolla research site is actively enrolling participants for this clinical trial. You'll receive care from experienced post-transplant lymphoproliferative disease specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.